Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways

Xinyan Wu, Muhammad Saddiq Zahari, Binyun Ma, Ren Liu, Santosh Renuse, Nandini A. Sahasrabuddhe, Lily Chen, Raghothama Chaerkady, Min Sik Kim, Jun Zhong, Christine Jelinek, Mustafa A. Barbhuiya, Pamela Leal-Rojas, Yi Yang, Manoj Kumar Kashyap, Arivusudar Marimuthu, Min Ling, Mary Jo Fackler, Vanessa Merino, Zhen ZhangCynthia A. Zahnow, Edward Gabrielson, Vered Stearns, Juan Carlos Roa, Saraswati Sukumar, Parkash S. Gill, Akhilesh Pandey

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we profiled the phosphotyrosine proteome of a panel of twenty-six TNBC cell lines using quantitative high resolution Fourier transform mass spectrometry. A heterogeneous pattern of tyrosine kinase activation was observed based on 1,789 tyrosine-phosphorylated peptides identified from 969 proteins. One of the tyrosine kinases, AXL, was found to be activated in a majority of aggressive TNBC cell lines and was accompanied by a higher level of AXL expression. High levels of AXL expression are correlated with a significant decrease in patient survival. Treatment of cells bearing activated AXL with a humanized AXL antibody inhibited cell proliferation and migration in vitro, and tumor growth in mice. Overall, our global phosphoproteomic analysis provided new insights into the heterogeneity in the activation status of tyrosine kinase pathways in TNBCs. Our approach presents an effective means of identifying important novel biomarkers and targets for therapy such as AXL in TNBC.

Original languageEnglish (US)
Pages (from-to)29143-29160
Number of pages18
JournalOncotarget
Volume6
Issue number30
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Phosphotyrosine
Protein-Tyrosine Kinases
Breast Neoplasms
Antibodies, Monoclonal, Humanized
Cell Line
Fourier Analysis
Proteome
Cell Movement
Tyrosine
Mass Spectrometry
Neoplasms
Biomarkers
Cell Proliferation
Surveys and Questionnaires
Phenotype
Peptides
Survival
Therapeutics
Growth

Keywords

  • AXL
  • Kinase
  • Protein phosphorylation
  • Proteomics
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. / Wu, Xinyan; Zahari, Muhammad Saddiq; Ma, Binyun; Liu, Ren; Renuse, Santosh; Sahasrabuddhe, Nandini A.; Chen, Lily; Chaerkady, Raghothama; Kim, Min Sik; Zhong, Jun; Jelinek, Christine; Barbhuiya, Mustafa A.; Leal-Rojas, Pamela; Yang, Yi; Kashyap, Manoj Kumar; Marimuthu, Arivusudar; Ling, Min; Fackler, Mary Jo; Merino, Vanessa; Zhang, Zhen; Zahnow, Cynthia A.; Gabrielson, Edward; Stearns, Vered; Roa, Juan Carlos; Sukumar, Saraswati; Gill, Parkash S.; Pandey, Akhilesh.

In: Oncotarget, Vol. 6, No. 30, 01.01.2015, p. 29143-29160.

Research output: Contribution to journalArticle

Wu, X, Zahari, MS, Ma, B, Liu, R, Renuse, S, Sahasrabuddhe, NA, Chen, L, Chaerkady, R, Kim, MS, Zhong, J, Jelinek, C, Barbhuiya, MA, Leal-Rojas, P, Yang, Y, Kashyap, MK, Marimuthu, A, Ling, M, Fackler, MJ, Merino, V, Zhang, Z, Zahnow, CA, Gabrielson, E, Stearns, V, Roa, JC, Sukumar, S, Gill, PS & Pandey, A 2015, 'Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways', Oncotarget, vol. 6, no. 30, pp. 29143-29160. https://doi.org/10.18632/oncotarget.5020
Wu, Xinyan ; Zahari, Muhammad Saddiq ; Ma, Binyun ; Liu, Ren ; Renuse, Santosh ; Sahasrabuddhe, Nandini A. ; Chen, Lily ; Chaerkady, Raghothama ; Kim, Min Sik ; Zhong, Jun ; Jelinek, Christine ; Barbhuiya, Mustafa A. ; Leal-Rojas, Pamela ; Yang, Yi ; Kashyap, Manoj Kumar ; Marimuthu, Arivusudar ; Ling, Min ; Fackler, Mary Jo ; Merino, Vanessa ; Zhang, Zhen ; Zahnow, Cynthia A. ; Gabrielson, Edward ; Stearns, Vered ; Roa, Juan Carlos ; Sukumar, Saraswati ; Gill, Parkash S. ; Pandey, Akhilesh. / Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. In: Oncotarget. 2015 ; Vol. 6, No. 30. pp. 29143-29160.
@article{c2059b50b8114457baf2b8e5e20c7fb5,
title = "Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways",
abstract = "Breast cancer is the most prevalent cancer in women worldwide. About 15-20{\%} of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we profiled the phosphotyrosine proteome of a panel of twenty-six TNBC cell lines using quantitative high resolution Fourier transform mass spectrometry. A heterogeneous pattern of tyrosine kinase activation was observed based on 1,789 tyrosine-phosphorylated peptides identified from 969 proteins. One of the tyrosine kinases, AXL, was found to be activated in a majority of aggressive TNBC cell lines and was accompanied by a higher level of AXL expression. High levels of AXL expression are correlated with a significant decrease in patient survival. Treatment of cells bearing activated AXL with a humanized AXL antibody inhibited cell proliferation and migration in vitro, and tumor growth in mice. Overall, our global phosphoproteomic analysis provided new insights into the heterogeneity in the activation status of tyrosine kinase pathways in TNBCs. Our approach presents an effective means of identifying important novel biomarkers and targets for therapy such as AXL in TNBC.",
keywords = "AXL, Kinase, Protein phosphorylation, Proteomics, Triple negative breast cancer",
author = "Xinyan Wu and Zahari, {Muhammad Saddiq} and Binyun Ma and Ren Liu and Santosh Renuse and Sahasrabuddhe, {Nandini A.} and Lily Chen and Raghothama Chaerkady and Kim, {Min Sik} and Jun Zhong and Christine Jelinek and Barbhuiya, {Mustafa A.} and Pamela Leal-Rojas and Yi Yang and Kashyap, {Manoj Kumar} and Arivusudar Marimuthu and Min Ling and Fackler, {Mary Jo} and Vanessa Merino and Zhen Zhang and Zahnow, {Cynthia A.} and Edward Gabrielson and Vered Stearns and Roa, {Juan Carlos} and Saraswati Sukumar and Gill, {Parkash S.} and Akhilesh Pandey",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5020",
language = "English (US)",
volume = "6",
pages = "29143--29160",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "30",

}

TY - JOUR

T1 - Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways

AU - Wu, Xinyan

AU - Zahari, Muhammad Saddiq

AU - Ma, Binyun

AU - Liu, Ren

AU - Renuse, Santosh

AU - Sahasrabuddhe, Nandini A.

AU - Chen, Lily

AU - Chaerkady, Raghothama

AU - Kim, Min Sik

AU - Zhong, Jun

AU - Jelinek, Christine

AU - Barbhuiya, Mustafa A.

AU - Leal-Rojas, Pamela

AU - Yang, Yi

AU - Kashyap, Manoj Kumar

AU - Marimuthu, Arivusudar

AU - Ling, Min

AU - Fackler, Mary Jo

AU - Merino, Vanessa

AU - Zhang, Zhen

AU - Zahnow, Cynthia A.

AU - Gabrielson, Edward

AU - Stearns, Vered

AU - Roa, Juan Carlos

AU - Sukumar, Saraswati

AU - Gill, Parkash S.

AU - Pandey, Akhilesh

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we profiled the phosphotyrosine proteome of a panel of twenty-six TNBC cell lines using quantitative high resolution Fourier transform mass spectrometry. A heterogeneous pattern of tyrosine kinase activation was observed based on 1,789 tyrosine-phosphorylated peptides identified from 969 proteins. One of the tyrosine kinases, AXL, was found to be activated in a majority of aggressive TNBC cell lines and was accompanied by a higher level of AXL expression. High levels of AXL expression are correlated with a significant decrease in patient survival. Treatment of cells bearing activated AXL with a humanized AXL antibody inhibited cell proliferation and migration in vitro, and tumor growth in mice. Overall, our global phosphoproteomic analysis provided new insights into the heterogeneity in the activation status of tyrosine kinase pathways in TNBCs. Our approach presents an effective means of identifying important novel biomarkers and targets for therapy such as AXL in TNBC.

AB - Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we profiled the phosphotyrosine proteome of a panel of twenty-six TNBC cell lines using quantitative high resolution Fourier transform mass spectrometry. A heterogeneous pattern of tyrosine kinase activation was observed based on 1,789 tyrosine-phosphorylated peptides identified from 969 proteins. One of the tyrosine kinases, AXL, was found to be activated in a majority of aggressive TNBC cell lines and was accompanied by a higher level of AXL expression. High levels of AXL expression are correlated with a significant decrease in patient survival. Treatment of cells bearing activated AXL with a humanized AXL antibody inhibited cell proliferation and migration in vitro, and tumor growth in mice. Overall, our global phosphoproteomic analysis provided new insights into the heterogeneity in the activation status of tyrosine kinase pathways in TNBCs. Our approach presents an effective means of identifying important novel biomarkers and targets for therapy such as AXL in TNBC.

KW - AXL

KW - Kinase

KW - Protein phosphorylation

KW - Proteomics

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84945161731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945161731&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5020

DO - 10.18632/oncotarget.5020

M3 - Article

C2 - 26356563

AN - SCOPUS:84945161731

VL - 6

SP - 29143

EP - 29160

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -